Symptomatic fibroids: The need to include low dose OCPs as a treatment option

Primary Care Update for Ob/Gyns

Volumn 7, Issue 1, 2000, Pages 46-48

  Sharafi, Khalida ^a   Kunze, Kimberly ^a   Nosher, John L ^a   Bachmann, Gloria A ^a  

^a Morristown Obstetrics and Gynecology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; GONADORELIN AGONIST; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; INCIDENCE; LEIOMYOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOM; TUMOR GROWTH; UTERUS MYOMA;

EID: 0033985212     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(99)00040-2     Document Type: Article

References (7)

1. Degligdish L., Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol. 23:1970;677-689.
2. Sampson J.A. The influence of myomata on the blood supply of the uterus with special reference to a uterine bleeding. Surg Gynecol Obstet. 16:1983;144-148.
3. Patazzimi F., Negri E., LaVechhia C., Rabaiott M., Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol. 79:1992;430-433.
4. Ross R.K., Pike M.C., Vessey M.P., Bull D., Yeates D., Casagrande J.T. Risk factors for uterine fibroids reduced risk associated with oral contraceptives. BMJ. 293:1986;359-362.
5. John A.H., Martin R. Growth of leiomyomata with estrogen-progestogen therapy. J Reprod Med. 6:1971;56-58.
6. Friedman A.J., Thomas P.P. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol. 85:1995;631-635.
7. Chan L., O'Malley B.W. Mechanism of action of the sex steroid hormones. N Engl J Med. 294:(26):1976;1430-1437.